SDGR

Schrodinger shares surged 7.6% to close at $32.6, driven by investor optimism following the announcement of Tectora, a new biotech company co-founded by Schrodinger, NEA, and RA Capital Management focused on immunology and inflammation therapies. The company secured $55 million in Series A funding.

Despite expected quarterly losses of $0.66 per share and a 15.3% revenue decline, consensus EPS estimates have been revised 72.2% higher over the past 30 days, suggesting potential for continued strength. SDGR carries a Zacks Rank #3 (Hold).

SOPHiA GENETICS reported a quarterly loss of $0.24 per share, missing consensus estimates of $0.13 loss by 84.62%, though revenues slightly exceeded expectations at $24.27 million. The stock has gained 52.3% year-to-date, significantly outperforming the S&P 500's 10.2% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market going forward.